Momelotinib not checked
Sierra Oncology LLC - a GSK company · GSK3070785 · GS-0387
FollowEvery change as it happens, and a Monday email
Trials
5 active
11 in total · 5 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- Tested for
- Primary Myelofibrosis (2 trials), VEXAS Syndrome, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
- Main trialPhase 2/3
- “This study will assess the efficacy and safety of momelotinib in participants with a diagnosis of VEXAS.”In the company’s words, NCT07569081 on ClinicalTrials.gov
- Other names
- GSK3070785 · GS-0387 · CYT387 · MMB
Other drugs for Primary Myelofibrosis
- NavitoclaxAbbVie · Phase 3
- NavtemadlinKartos Therapeutics, Inc. · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- ElriterceptTakeda · Phase 3
- PelabresibNovartis · Phase 3
Coming up4
- 11 DecPhase 2 trial completes · ClinicalTrials.gov
- 16 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
- 14 Jul 2027Phase 2 trial completes · ClinicalTrials.gov
- 6 Dec 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Not yet recruiting | 6 Dec 2028 | A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome | |
| Phase 2Active, not recruiting | 11 Dec 2026 | Extended Access of Momelotinib in Adults With Myelofibrosis | |
| Phase 2Recruiting | 16 Mar 2027 | Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis | |
| Phase 2Recruiting | 14 Jul 2027 | A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome | |
| Phase 3Completed | 28 Jul 2016 | Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF | |
| Phase 3Completed | 12 Sep 2016 | Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis | |
| Phase 3Terminated | 10 Apr 2017 | Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | |
| Phase 3Completed | 3 Dec 2021 | A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) | |
| Phase 2Completed | 18 Jul 2017 | Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | |
| Phase 2Completed | 6 Dec 2018 | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia | |
| Phase 1/2Authorised | not given | Melanoma-TBK1-inhibitor enhanced Immuno Therapy with Checkpoint Inhibitors: a Phase IB/II Trial in Unresectable Stage III or Stage IV Cutaneous Melanoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026